Cabot-wellington Lowers stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Cabot-wellington reduced its stake in Gilead Sciences by 3.33% during the most recent quarter end. The investment management company now holds a total of 147,903 shares of Gilead Sciences which is valued at $11,768,642 after selling 5,100 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Gilead Sciences makes up approximately 9.91% of Cabot-wellington’s portfolio.

Other Hedge Funds, Including , Edge Asset Management Inc boosted its stake in GILD in the latest quarter, The investment management firm added 48,050 additional shares and now holds a total of 276,818 shares of Gilead Sciences which is valued at $22,073,467. Gilead Sciences makes up approx 0.19% of Edge Asset Management Inc’s portfolio.Integral Derivatives reduced its stake in GILD by selling 21,523 shares or 62.06% in the most recent quarter. The Hedge Fund company now holds 13,156 shares of GILD which is valued at $1,057,874. Gilead Sciences makes up approx 0.41% of Integral Derivatives’s portfolio.Foster Motley Inc reduced its stake in GILD by selling 5,785 shares or 7.91% in the most recent quarter. The Hedge Fund company now holds 67,347 shares of GILD which is valued at $5,393,821. Gilead Sciences makes up approx 1.04% of Foster Motley Inc’s portfolio.Nippon Life Insurance Co reduced its stake in GILD by selling 6,926 shares or 10.72% in the most recent quarter. The Hedge Fund company now holds 57,682 shares of GILD which is valued at $4,619,751. Gilead Sciences makes up approx 0.11% of Nippon Life Insurance Co’s portfolio. Park Avenue Securities sold out all of its stake in GILD during the most recent quarter. The investment firm sold 2,418 shares of GILD which is valued $197,768.

Gilead Sciences opened for trading at $79.46 and hit $80.87 on the upside on Wednesday, eventually ending the session at $80.7, with a gain of 1.83% or 1.45 points. The heightened volatility saw the trading volume jump to 1,05,83,799 shares. Company has a market cap of $106,496 M.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.